Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

European Society of Cardiology (ESC) Congress - 2025

August 29 - September 1, 2025

Farxiga (dapagliflozin)
Chronic Kindey Disease
Dyslipidemia
Hypertension
Heart Failure/Chronic Kidney Disease
Heart Failure
Wainua (eplontersen)
ATTR Amyloidosis
Type 2 Diabetes
Major bleeding
Lokelma (Sodium zirconium cyclosilicate)

Rare coding variant architecture of atrial fibrillation

A value-based analysis of the systematic use of dapagliflozin in patients with heart failure

EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis

Modelling the effect of the early initiation of disease-modifying therapy in community-based patients with suspected heart failure

Leveraging AI and Clinical Guidelines to Identify Undiagnosed and Under-treated CKD Patients for Treatment Optimisation

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

The InspeCKD study - Chronic Kidney Disease (CKD) in Germany Primary Care: Impact of CKD Diagnosis on CKD Therapy in Patients with Heart Failure

PDF

Laroprovstat (AZD0780), a novel, oral PCSK9 inhibitor with properties allowing for broad use,food-intake independency and co-administration with other lipid-lowering therapies

High prevalence of aldosterone dysregulation in hypertensive adults tested for aldosterone and renin levels

PDF

Risk of cardiorenal and metabolic outcomes in inadequately controlled hypertension: insights from the ENLIGHTN study

pdf

BaxHTN - Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

PDF

Outcomes of aldosterone dysregulation in routine clinical care ADEL (Aldosterone Dysregulation Epidemiology Landscape) – a population-based study

PDF

Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

Development and implementation of a heart failure dashboard for England: nationwide study of 1.4 million primary and secondary health care records

WATCH-HF (Awareness of prevalence, diagnosis and treatment of chronic Heart Failure in at-risk-patients in German primary care) - A real-world data analysis of chronic HF management in Germany

Unveiling Gaps in Heart Failure Management in Germany: A Retrospective Analysis of National Data and Healthcare Utilisation Patterns

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

pdf

Atrial structure and function in patients with amyloidosis: findings from the NEURO-TTRansform study

PDF

Early Symptoms and Medical History of Patients with Transthyretin Amyloidosis Cardiomyopathy: Results from the Multi-Country OverTTuRe Study

The Incidence of Death and Risk Factors for Mortality in Cardiac Amyloidosis: An Observational Study in the UK Clinical Setting Using Electronic Health Records

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

pdf

MaesTTRo: Initial findings from a pioneering prospective multi-country real-world study of patients with transthyretin amyloidosis

The impact of microalbuminuria and proteinuria on cardiovascular outcomes in individuals with type 2 diabetes mellitus. A population-based, electronic health records study

Factor Xa inhibitor associated major bleeding characteristics, burden, and health resource utilization in Alberta, Canada - an observational population based study

Hyperkalaemia in patients with heart failure in German primary care practices: prevalence, diagnosis, and treatment: The WATCH-K study

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização